Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06767462 · ClinicalTrials.gov registry record
An Ophthalmic Safety Study in Patients With Breast Cancer
A clinical trial of Ophthalmic Safety in Patients With Breast Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- 160
- Enrollment target
- 20
- Study locations
NCT06767462: Recruiting study of Ophthalmic Safety in Patients With Breast Cancer, sponsored by AstraZeneca.
NCT06767462 is a study of Ophthalmic Safety in Patients With Breast Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 160 participants. The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06767462, a study of Ophthalmic Safety in Patients With Breast Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
To assess ophthalmic health in parallel cohorts of patients with breast cancer
Primary Outcome
To detect potential impairment in central vision in patients with breast cancer.
Conditions Studied
Study Locations (20)
Other
- Research Site - Buenos Aires
- Research Site - Buenos Aires
- Research Site - CABA
- Research Site - Córdoba
- Research Site - San Miguel de Tucumán
- Research Site - San Miguel de Tucumán
- Research Site - Edegem
- Research Site - Leuven
California
- Research Site - La Jolla
- Research Site - Palo Alto
- Research Site - San Diego
Pennsylvania
- Research Site - Clairton
- Research Site - Pittsburgh
Iowa
- Research Site - Iowa City
New York
- Research Site - New York
North Carolina
- Research Site - Winston-Salem
Ohio
- Research Site - Cleveland
South Dakota
- Research Site - Sioux Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-03-04 |
| Est. Completion | 2027-07-06 |
What NCT06767462 shows while recruiting
NCT06767462 is an observational study that tracks outcomes without assigning an intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Ophthalmic Safety in Patients With Breast Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06767462 names 20 study sites across 10 states, led by Other, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06767462 about?
NCT06767462 is a clinical study titled "An Ophthalmic Safety Study in Patients With Breast Cancer". To assess ophthalmic health in parallel cohorts of patients with breast cancer
What is the current status of trial NCT06767462?
This trial is currently recruiting. The enrollment target is 160 participants. The study started on 2025-03-04. Estimated completion is 2027-07-06.
What conditions does trial NCT06767462 study?
This clinical trial studies the following conditions: Ophthalmic Safety in Patients With Breast Cancer.
Who is sponsoring clinical trial NCT06767462?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06767462 being conducted?
This trial has 20 study locations across California, Iowa, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI